Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederic Blanc

Showing results (61-70 of 88) with videos related to

Pageof 9
Sort By:
The Lancet. Oncology|June 23, 2015
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trialAndrew X Zhu, Joon Oh Park, Baek-Yeol Ryoo, et al.
Medical Image Analysis|October 2, 2020
The reliability of a deep learning model in clinical out-of-distribution MRI data: A multicohort studyGustav Mårtensson, Daniel Ferreira, Tobias Granberg, et al.
Cardiovascular and Interventional Radiology|November 19, 2021
Evaluating the Effectiveness of Yttrium-90 Glass Microspheres in the Treatment of Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, and Metastatic Colorectal Cancer in Practice: Protocol for the Prospective PROACTIF Phase IV Registry Study in FranceEtienne Garin, Jean-Baptiste Pinaquy, Clement Bailly, et al.
Liver Cancer|September 26, 2022
Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic HepatocholangiocarcinomaElia Gigante, Christian Hobeika, Brigitte Le Bail, et al.
European Journal of Cancer (Oxford, England : 1990)|June 8, 2017
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH studyIan Chau, Markus Peck-Radosavljevic, Christophe Borg, et al.
European Journal of Cancer (Oxford, England : 1990)|July 5, 2018
Corrigendum to 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study' [Eur J Canc 81 (2017) 17-25]Ian Chau, Markus Peck-Radosavljevic, Christophe Borg, et al.
Current Alzheimer Research|January 11, 2018
Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF BiomarkersOlivier Vercruysse, Claire Paquet, Audrey Gabelle, et al.
The New England Journal of Medicine|July 5, 2018
Cabozantinib in Patients with Advanced and Progressing Hepatocellular CarcinomaGhassan K Abou-Alfa, Tim Meyer, Ann-Lii Cheng, et al.
Nature Genetics|March 31, 2015
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targetsKornelius Schulze, Sandrine Imbeaud, Eric Letouzé, et al.
The Lancet. Gastroenterology & Hepatology|April 8, 2019
Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trialPhilippe Merle, Jean-Frederic Blanc, Jean-Marc Phelip, et al.
Pageof 9

Showing results (61-70 of 88) with videos related to

Sort By:
Pageof 9
The Lancet. Oncology|June 23, 2015
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trialAndrew X Zhu, Joon Oh Park, Baek-Yeol Ryoo, et al.
Medical Image Analysis|October 2, 2020
The reliability of a deep learning model in clinical out-of-distribution MRI data: A multicohort studyGustav Mårtensson, Daniel Ferreira, Tobias Granberg, et al.
Cardiovascular and Interventional Radiology|November 19, 2021
Evaluating the Effectiveness of Yttrium-90 Glass Microspheres in the Treatment of Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, and Metastatic Colorectal Cancer in Practice: Protocol for the Prospective PROACTIF Phase IV Registry Study in FranceEtienne Garin, Jean-Baptiste Pinaquy, Clement Bailly, et al.
Liver Cancer|September 26, 2022
Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic HepatocholangiocarcinomaElia Gigante, Christian Hobeika, Brigitte Le Bail, et al.
European Journal of Cancer (Oxford, England : 1990)|June 8, 2017
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH studyIan Chau, Markus Peck-Radosavljevic, Christophe Borg, et al.
European Journal of Cancer (Oxford, England : 1990)|July 5, 2018
Corrigendum to 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study' [Eur J Canc 81 (2017) 17-25]Ian Chau, Markus Peck-Radosavljevic, Christophe Borg, et al.
Current Alzheimer Research|January 11, 2018
Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF BiomarkersOlivier Vercruysse, Claire Paquet, Audrey Gabelle, et al.
The New England Journal of Medicine|July 5, 2018
Cabozantinib in Patients with Advanced and Progressing Hepatocellular CarcinomaGhassan K Abou-Alfa, Tim Meyer, Ann-Lii Cheng, et al.
Nature Genetics|March 31, 2015
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targetsKornelius Schulze, Sandrine Imbeaud, Eric Letouzé, et al.
The Lancet. Gastroenterology & Hepatology|April 8, 2019
Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trialPhilippe Merle, Jean-Frederic Blanc, Jean-Marc Phelip, et al.
Pageof 9